Sound Bioventures

Sound Bioventures is a venture capital firm dedicated to investing in private companies in Europe and the USA that are in about-to-be clinical or clinical stages. The firm focuses on developing novel medicines designed to address significant unmet medical needs. Their investment strategy emphasizes supporting companies as they enter the most value-generating phases of drug development, aiming to answer the critical question of whether a drug is effective. Sound Bioventures is registered as an alternative investment fund under the Swedish Alternative Investment Funds Managers Act.

The firm's origins trace back to a Danish-Swedish collaboration, founded by Casper Breum (Danish) and Johan Kördel (Swedish). The name "Sound Bioventures" is inspired by the Öresund (or Øresund), the stretch of water connecting Denmark and Sweden, reflecting their Scandinavian roots and international outlook. While rooted in the Medicon Valley region, their investment activities are designed to span across Europe and the USA, with a particular emphasis on companies with Scandinavian ties.

Sound Bioventures maintains a diverse portfolio of biotechnology companies, including Aboleris, AnaCardio, Artax Biopharma, Arthex, BOOST Pharma, Breye Therapeutics, NephroDI, Teitur, Theolytics, and VarmX. These companies are engaged in developing therapies for various conditions, such as heart failure, autoimmune diseases, neurodegenerative diseases, and reversing the action of anticoagulants. The firm's first fund successfully raised €110 million, anchored by significant investors like Novo Holdings, Saminvest, Vækstfonden, the European Investment Fund (EIF), and Ramsbury Invest.

The leadership team at Sound Bioventures includes Managing Partners Casper Breum and Johan Kördel, along with Principals Ester Sklarsky, Anna Gran, and Linda Spahiu Elvesjö, and Office Manager Anne Marie Simon. Bibhash Mukhopadhyay was also part of the founding team. The team brings extensive experience in life sciences and drug development, with a strong preference for scientific or medical education and operational experience in the biotech or pharmaceutical industry. They are committed to a proactive approach to ESG issues within their investment and portfolio management processes.